CNAT—Is the biology really so black and white? Surely, there are many instances in which intervening in a given pathway can have both positive and negative consequences.
Caspase inhibition made sense to PFE and GILD, both of whom took drugs from this class into clinical trials. (CNAT’s drug is the one previously owned by PFE.)
GILD is currently testing an ASK-1 inhibitor in NASH. Its purported MoA is inhibiting apoptosis.
News 
Market Data 
Discover 
